Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EFTR | US
0
0%
Healthcare
Biotechnology
31/03/2024
21/10/2024
0.00
0.00
0.00
0.00
eFFECTOR Therapeutics Inc. a clinical-stage biopharmaceutical company engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E) which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics Inc. was incorporated in 2012 and is headquartered in Solana Beach California.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
663.1%1 month
570.7%3 months
337.2%6 months
311.9%-
-
0.01
23.15
0.71
-0.41
-
-
-32.59M
5.64K
5.64K
-
-
-
117.00
-946.56
0.97
1.97
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.04
Range1M
0.04
Range3M
0.06
Rel. volume
0.12
Price X volume
4.54
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Calithera Biosciences Inc | CALA | Biotechnology | 0.001 | 4.87K | -50.00% | n/a | 8.17% |
XOMAP | XOMAP | Biotechnology | 26.24 | 0 | -0.23% | 26.27 | 121.93% |
XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock | XOMAO | Biotechnology | 25.5992 | 0 | 0.02% | 25.57 | 121.93% |
SABSW | SABSW | Biotechnology | 0.0534 | 0 | 8.54% | 0.17 | 11.58% |
Revolution Medicines Inc. Warrant | RVMDW | Biotechnology | 0.1195 | 0 | 18.32% | n/a | 5.40% |
REVBW | REVBW | Biotechnology | 0.0129 | 0 | -3.01% | n/a | 0.00% |
Rocket Pharmaceuticals Inc. Warrant | RCKTW | Biotechnology | 0.0666 | 0 | -6.06% | n/a | 0.00% |
OCEAW | OCEAW | Biotechnology | 0.0398 | 0 | 2.58% | n/a | -16.02% |
Nutriband Inc. Warrant | NTRBW | Biotechnology | 1.15 | 0 | 9.52% | n/a | 1.72% |
NKGen Biotech Inc. Warrants | NKGNW | Biotechnology | 0.032 | 0 | 29.03% | n/a | -40.33% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
No data |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.41 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 0.01 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 337.21 | 72.80 | Riskier |
Debt to Equity | 23.15 | -1.23 | Expensive |
Debt to Assets | 0.71 | 0.25 | Expensive |
Market Cap | 5.64K | 3.66B | Emerging |